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Abstract
Background: Only limited data has been reported so far regarding oesophageal cancer (EC) in elderly patients.
The aim of the study is to identify the baseline parameters that influenced therapeutic decision.
Methods: All consecutive patients 70 years or older being treated for EC were retrospectively analyzed. Patients
without visceral metastasis were divided into two groups: treatment with curative intent (chemoradiotherapy,
surgery, radiotherapy, mucosectomy or photodynamic therapy) or best supportive care (BSC). Patients with
metastasis were divided into two groups: palliative treatment (chemotherapy, chemoradiotherapy or radiotherapy)
or BSC.
Results: Two hundred and eighty-two patients were studied. Mean age was 76.5 ± 5.5 years and 22.4% of patients
had visceral metastasis. In patients without visceral metastasis (n = 220) the majority had treatment with curative
intent (n = 151) whereas in patients with metastasis (n = 62) the majority had BSC (n = 32). Severe adverse events
(≥ grade 3) were observed in only 17% of the patients. Patients without specific carcinologic treatment were older,
had more weight loss, worse WHO performance status and Charlson score in multivariate analysis.
Discussion: Our results suggest that elderly patients with an EC could benefit from cancer treatment without
major toxicities. Weight loss, WHO performance status and the Charlson score could be used to select the
appropriate treatment in an elderly patient.
Background
In the USA, oesophageal cancer (EC) occurs in patients
over 60 and 75 years of age in 44% and 30% respectively
[1]. Similar data have been published in different Eur-
opean countries [2]. Management of elderly patients
with EC remains a therapeutic challenge and the most
relevant treatment modalities are still being debated.
Although survival improvement has been observed over
the past decade, EC treatment continues to be signifi-
cantly influenced by age [3]. Moreover, it has also been
reported that elderly patients have undergone less sur-
gery, radiotherapy and chemotherapy than younger
patients [4].
To our knowledge, no specific data have been pub-
lished regarding therapeutic strategy in elderly patients
with EC. Despite progress in surgical practice, oesopha-
gectomy is associated with significant morbidity and
mortality, and 75 years is often considered as the age
limit for this type of surgery [5]. Definitive chemora-
diotherapy (CRT) has been considered with curative
intent in locally advanced or inoperable non-metastatic
EC [6-9] but few studies have evaluated this treatment
in elderly patients [10,11]. To our knowledge there is no
reported data about the clinical or tumor characteristics
that could influence treatment decisions in elderly
patients with EC. Nevertheless, it is crucially important
that clinicians have criteria for therapeutic decisions.
The aim of the study was to identify the baseline para-
meters that influenced both the therapeutic decision and
outcomes in elderly patients with EC.
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Patient inclusion
All patients 70 years or older with an EC hospitalized in
the Gastroenterology Department of Rouen University
Hospital between January 1994 and December 2007
were retrospectively evaluated. The local ethics commit-
tee approved the procedure and, due to the retrospective
analysis with a majority of dead patients, no patient con-
sent was necessary. Patient and tumor baseline charac-
teristics were collected. Degree of dysphagia was
evaluated according to the Atkinson score [12]. Charl-
son score based on nineteen medical conditions for the
analysis of patient’s comorbidities was used [13]. The
tumor staging was based on the 1983 AJCC staging sys-
tem according to published recommendations. Tumor
TNM stage was based on esophagoscopy, barium eso-
phagography, chest and abdominal computed tomogra-
phy (CT-scan) and esophageal ultrasonography when it
was feasible.
Treatment regimen
In our institution, since the validation of definitive CRT
and in accordance with the international guidelines,
there was no major modification of oesophageal carci-
noma therapeutic strategy during the period of the
study [6,7]. The different treatment options were endo-
scopic resection (mucosectomy), photodynamic therapy
(PDT), surgical resection, chemoradiotherapy, radiother-
apy (RT) or chemotherapy (CT). For each patient, the
therapeutic strategy was discussed in multidisciplinary
meetings with the gastroenterologist, surgeon, oncologist
and radiotherapist. The decision-making process was
based not on predefined variables but with consideration
of multiple doctors’ o p i n i o n sa n do na ni n d i v i d u a lb a s i s
taking into account age, albumin rate, loss of weight,
comorbidities and performance status. In general, if
there were several criteria including age > 75 years,
albumin < 30 g/l, loss of weight > 10%, multiple severe
comorbidities and WHO performance status > 1 meant
that there was a contradiction for aggressive treatment
(surgery, RCT or chemotherapy).
Mucosectomy and PDT were routinely reserved for in
situ tumors (Tis) but also carried out in elderly patients
with stage I oesophageal carcinoma and a contraindica-
tion for surgery (severe comorbidities) [14]. In our insti-
tution, elderly patients with stage II tumors underwent
surgical resection or definitive CRT. Two operative
approaches were used at the surgeon’s discretion: the
Ivor-Lewis transthoracic oesophagectomy with a 2-field
lymphadenectomy or the transhiatal oesophagectomy
with abdominal lymphadenectomy and limited mediast-
inal lymph node resection. Nevertheless, a majority of
these patients received a CRT regimen with curative
intent due to surgical contraindication. Patients with
stage III tumors had definitive CRT based on the cispla-
tin and 5-fluorouracil (CDDP/5FU) combination as
described by Herskovic et al [15] or the CDDP/irinote-
can combination reported by Michel et al [16]. The
radiotherapy dose was 50-55 Grays (Gy), delivered 5
days a week at 1.8 Gy/day, based on the international
recommendations [6,7]. Salvage surgery could be per-
formed in patients without clinical complete response
and no metastases. Chemotherapy used in metastatic
patients was principally CDDP/5FU regimen. Patients
with severe malignant dysphagia and/or esorespiratory
fistula and/or a contraindication for CRT or surgery
(primarily severe comorbidities or a metastatic disease
at diagnosis) were treated by self-expanding metallic
stent (SEMS).
All severe adverse events defined as a toxicitiy grade ≥
3 during CT (based on National Cancer Institute Com-
mon Toxicity Criteria version 2.0) or life-threatening
complications after surgery or endoscopic treatment
were recorded.
Outcome and follow-up
In patients treated with curative strategy, a clinical com-
plete response (CCR) was defined by no residual tumor
on upper digestive endoscopy and no metastatic disease
occurrence on CT-scan. This evaluation was performed
approximately 2 months after curative treatment. In
metastatic patients, chemotherapy efficacy was evaluated
according to RECIST criteria. Follow-up data were
updated in December 2008.
Statistical analysis
Two independent analyses were performed according to
the metastatic status of patients (stage I to III and M1a
versus M1b). In patients without metastases two groups
were compared: patients treated with curative intent
(mucosectomy and PDT for Tis or T1N0M0, surgery,
CRT or RT) and those treated by best supportive care
(BSC) (SEMS or any specific treatment). In metastatic
patients two groups were compared: patients treated by
CT, CRT or RT and those treated by BSC.
We performed an analysis of factors influencing treat-
ment strategy in univariate and multivariate logistic
regression analyses. Groups were compared using Fish-
er’s exact test and Student’s t-test as appropriate. Any
variables reaching p = 0.05 were introduced in multi-
variate analysis.
Survival curve was established using the Kaplan-Meier
method and compared with Log-rank test. Predictive
factors of overall survival were studied by univariate
analysis and further evaluated in multivariate Cox
regression analysis to estimate the hazard ratio (HR)
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variables for the univariate analysis were: sex, age ≥ 75
years, WHO performance status < 2, initial weight loss
< 10%, Charlson score ≤ 1, histology, tumor stage and
treatment. Any variables reaching p =0 . 0 5w e r ei n t r o -
duced in multivariate analysis.
All statistical analyses were performed with a two-side
significance value of 0.05. Statistical analysis was per-
formed using the Statview software (Statview for Win-
dows, SAS Institut Inc., version 5.0).
Results
Patient and tumor characteristics
Two hundred and eighty-two patients over 70 years of
age were assessed (among 904 patients with esopha-
geal cancer). In patients without visceral metastasis
(n = 220), 151 and 69 had a potential curative treat-
ment and best supportive care respectively (Fig. 1).
In patients with metastatic disease (n = 62), 32 had
BSC and 30 had palliative treatment. Mean age was
76.5 ± 5.5 (range 70 to 96 years) (Table 1). The pre-
valence of patients with comorbidities, according to
the Charlson score, was 69.3%. Fifty-five patients
(21.6%) had a prior or concurrent malignancy, 45
patients (17.7%) chronic obstructive pulmonary dis-
ease, 38 patients (15.0%) myocardial infarction, 30
patients (11.8%) peripheral vascular disease, 29
patients (11.4%) diabetes and 24 patients (9.4%) con-
gestive heart failure. The majority of patients had
stage II or III tumors (Table 2).
Treatment of patients without visceral metastasis
In patients without visceral metastasis (n = 220), treat-
ment with curative intent was performed in 151 patients
(68.6%). (Table 3). Severe adverse effects were reported
in 20.5% patients. Sixty-nine patients (31.4%) had no
curative treatment as they were older (80 versus 74.9
years, p < 0.01), had worse creatinine clearance (52.5
versus 72.4, p < 0.01), worse albumin rate (31.4 versus
37.7, p < 0.01), greater loss of weight (64.7% versus
28.4% loss of weight ≥ 10%, p < 0.01), worse WHO per-
formance status (20.4% versus 79.3% WHO performance
status at 0 or 1, p < 0.01) or worse Charlson score
(18.2% versus 38.5% Charlson score at 0, p < 0.01). In
multivariate analysis, age (p = 0.02), loss of weight
(p= 0.03), WHO performance status (p = 0.03) and Charl-
son score (p = 0.03) were significantly associated with BSC.
Twenty patients had a mucosectomy or PDT because
the tumor was T1N0M0. Both treatments permitted 14
patients to achieve clinical complete response without
major complications but 7 patients had a local
recurrence.
Most of the patients benefited from CRT because in our
institution all patients with stage III disease and/or surgical
contradictions were treated by CRT. Selection was based
on age (mean age of 74.3 ± 3.7), WHO performance status
(79.8% WHO 0 or 1) and loss of weight (67.8% inferior to
10%). Twenty-seven patients (24.3%) experienced adverse
effects ≥ grade 3, mainly vomiting and neutropenia. Sixty-
four patients (57.6%) had a CCR and 27 (24.3%) had no
recurrence during the follow-up. Local recurrence was
Figure 1 Patient stratification. * Two patients had a treatment with chemotherapy, others had best supportive care.
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with CCR to CRT. Median overall survival was 17.5 ± 1.0
months and 2-year survival was 36.6%.
Thirteen patients underwent initial surgery and seven
had salvage treatment due to no CCR to CRT or local
recurrence. Mean age was 73.5 ± 2.6. No patients had
adjuvant therapy. Four had severe post-operative com-
plications (two patients died) and ten had tumor recur-
rence. During a follow-up of 27.5 months, local
recurrence was 20% and metastasis occurrence was 35%.
Median overall survival was 26.4 ± 7.9 months and
2-year survival was 58.8%.
Treatment of patients with visceral metastasis
In patients with M1b disease (n = 62), 30 patients bene-
fited from palliative treatment (table 3). Thirty-two
patients had BSC as they were older (78.2 versus 74.2
years, p < 0.01), and had worse WHO performance sta-
tus (26.9% versus 70% WHO performance status at 0 or
1, p < 0.01) and worse albumin rate (28.7 versus 35.2, p
< 0.01). None of these criteria were significant in multi-
variate analysis.
In patients treated by CT (n = 20), 7 had adverse
effects ≥ grade 3. At first evaluation (3 months), seven
patients had a stable disease or a partial response to CT.
Table 1 Patient characteristics
All patients
(n = 282)
Patients without visceral metastasis
(n = 220)
Patients with visceral metastasis
(n = 62)
Curative treatment
(n = 151)
BSC
(n = 69)
Palliative treatment
(n = 30)
BSC
(n = 32)
Age
year, SD
≥ 75 years
76.5 ± 5.5 74.9 ± 4.1 80.0 ± 6.6* 74.2 ± 4.0 78.2 ± 5.8 **
145 (51.4%) 62 (41.1%) 50 (72.5%) * 12 (40%) 21 (65.6%)
Gender ratio
(men/women)
216/66 (76.6%) 124/27(82.1%) 38/31 (55.1%) * 27/3 (90%) 27/5 (84.3%)
WHO performance status
‡ (n = 260)
0 39 (15.0%) 35 (23.3%) 0 * 3 (10.0%) 1 (3.8%) **
1 119 (45.8%) 84 (56.0%) 11 (20.4%) 18 (60.0%) 6 (23.1%)
2 93 (35.8%) 31 (20.7%) 38 (70.4%) 8 (26.7%) 16 (61.5%)
3 9 (3.5%) 0 5 (9.3%) 1 (3.3%) 3 (11.5%)
Atkinson dysphagia score
† (n = 270)
0 31 (11.5%) 20 (13.2%) 7 (11.3%) * 2 (6.9%) 2 (7.1%)
1 9 (25.5%) 43 (28.5%) 6 (9.7%) 14 (48.3%) 6 (21.4%)
2 129 (47.8%) 65 (43.0%) 39 (62.9%) 10 (34.5%) 15 (53.6%)
3 30 (11.1%) 16 (10.6%) 7 (11.3%) 3 (10.3%) 4 (14.3%)
4 11 (4.1%) 7 (4.6%) 3 (4.8%) 0 1 (3.6%)
Initial weight loss
† (n = 219, SD) 8.4 ± 7.7 6.7 ± 6.6 12.4 ± 11.3 * 9.0 ± 5.6 13.6 ± 10.0 **
Initial weight loss ≥ 10%
† 84 (38.4%) 40 (28.4%) 22 (64.7%) * 11 (40.7%) 11 (64.7%)
Initial albumin
† (n = 148, g/l, SD) 35.2 ± 6.9 37.7 ± 5.4 31.4 ± 8.0 * 35.2 ± 4.8 28.7 ± 6.2 **
Creatinine clearance
† (n = 172, mL/min, SD) 67.1 ± 24.5 72.4 ± 22.7 52.5 ± 23.3 * 76.1 ± 22.5 60.9 ± 26.4
Charlson score
†
(n = 254)
Mean 1.4 1.3 1.7 1.2 1.6
Charlson score at 0 78 (30.7%) 50 (38.5%) 12 (18.2%) * 8 (28.6%) 8 (26.7%)
n: number of patients, SD: standard deviation, g/l: gram per liter, mL/min: milliter per minute,
BSC: best supportive care, *: p < 0.05 curative treatment vs BSC, **: p < 0.05 palliative treatment vs BSC,
†: not available for all patients
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On the whole, 133 patients (47.2%) initially had a pallia-
tive treatment for dysphagia (Table 3). After SEMS pla-
cement, 6 patients suffered a severe complication
(aspiration pneumonia) with one death. After oesopha-
geal dilatation without stent placement, one patient had
pneumonia following treatment. One hundred and one
patients had BSC alone and the majority had a SEMS
placement for dysphagia palliation (54.4%).
Outcome and overall survival
After 80 years, no patient without visceral metastasis
(n = 50) benefited from surgery and only eight from
CRT. Concerning patients with visceral metastasis older
than 80 years (n = 13) only 1 patient had chemotherapy.
Dysphagia improvement with treatment was observed
in 60.7% of the evaluated patients with no difference
between groups (Table 3). After SEMS placement, few
dysphagia recurrences were observed (n = 9/63).
The median overall survival was 9.7 ± 1.0 months
(Fig. 2) and specific survival was 11.5 ± 0.7 months
(Table 4). Among non-metastatic patients, median over-
all survival was 17.8 ± 1.5 months in the curative treat-
ment group versus 5.5 ± 2.0 months in the BSC group
(Fig. 3). Predictive factors of overall survival in multi-
v a r i a t ea n a l y s i sw e r eaW H Op e r f o r m a n c es t a t u s<2
(p < 0.01), initial weight loss < 10% (p =0 . 0 1 ) ,a ne a r l y
tumoral stage (p < 0.01) and a carcinologic treatment
(p < 0.01) but neither age nor comorbidities were con-
sidered factors (Table 5).
Discussion
This study highlights the clinical practice in our institu-
tion. The main results were: (i) the prognosis of oeso-
phageal cancer in elderly patients remains poor (median
overall survival at 10 months) (ii) among patients with-
out metastasis, 68.6% underwent a treatment with cura-
tive intent but among patients with a M1b disease the
majority had BSC (51.6%) (iii) selected patients with
good performance status, good nutritional status and
without major comorbidities were able to benefit from
curative treatment or chemotherapy without major
Table 2 Tumor characteristics
All patients (n = 282) Patients without visceral metastasis
(n = 220)
Patients with visceral metastasis (n = 62)
Curative treatment (n = 151) BSC
(n = 69)
Palliative treatment (n = 30) BSC
(n = 32)
Tumoral stage
stage I 27 (9.7%) 24 (15.9%) 3 (4.3%) - -
stage II 68 (24.5%) 61 (40.4%) 7 (10.1%) - -
stage III 69 (24.9%) 51 (33.8%) 18 (26.1%) - -
stage IV (M1a) 8 (2.9%) 7 (4.6%) 1 (1.4%) - -
stage IV (M1b) 62 (22.4%) - - 30 (100%) 32 (100%)
unknown but M0 48 (17.0%) 8 (5.3%) 40 (58.0%) - -
Tumoral location
lower third 151 (53.5%) 80 (60.0%) 37 (53.6%) 19 (63.3%) 15 (46.9%)
middle third 86 (30.6%) 44 (29.1%) 21 (30.4%) 9 (30.0%) 12 (37.5%)
upper third 45 (16.0%) 27 (17.9%) 11 (15.9%) 2 (6.7%) 5 (15.6%)
Mean tumor length
†
(n = 199, cm, SD)
5.2 ± 2.5 4.7 ± 2.3 5.4 ± 2.6 5.9 ± 1.8 7.2 ± 3.2
Tumor length ≥ 5c m
† 116/199 (58.3%) 66/124 (53.2%) 25/43 (58.1%) 11/14 (78.6%) 14/18 (77.8%)
Mean tumor diameter
†
(n = 81, cm, SD)
2.7 ± 1.3 2.6 ± 1.2 4.1 ± 1.2 * 2.5 ± 0.7 1.9 ± 0.1
Histological type
† (n = 271)
SCC 183 (67.5%) 103 (70.1%) 45 (70.3%) 17 (56.7%) 18 (60.0%)
adenocarcinoma 83 (30.6%) 44 (29.9%) 18 (28.1%) 12 (40.0%) 9 (30.0%)
other 5 (1.8%) 0 1 (1.5%) 1 (3.3%) 3 (10.0%)
n: number of patients, cm: centimeter, SD: standard deviation, BSC: best supportive care,
SCC: squamous cell carcinoma, *: p < 0.05 curative treatment vs BSC,
†: not available for all patients
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All patients (n = 282) Patients without visceral metastasis
(n = 220)
Patients with visceral metastasis
(n = 62)
Curative treatment (n = 151) BSC
(n = 69)
Palliative treatment (n = 30) BSC
(n = 32)
Dysphagia palliative treatment
naso-gastric tubes 15 (5.3%) 7 (4.6%) 4 (5.8%) * 3 (10.0%) 1 (3.1%) **
gastrostomy 11 (3.9%) 4 (2.6%) 6 (8.7%) 0 1 (3.1%)
endoscopic dilation 44 (15.6%) 19 (12.6%) 14 (20.3%) 5 (16.7%) 5 (3.1%)
oesophageal stent 63 (22.3%) 3 (2.0%) 37 (53.6%) 5 (16.7%) 18 (3.1%)
Initial cancer treatment
Mucosectomy 6 (2.1%) 6 (4.0%) - - -
PDT 18 (6.4%) 14 (9.3%) 3 (4.3%) 1 (3.3%) -
Surgery 13 (4.6%) 13 (8.6%) - - -
Chemoradiotherapy 119 (42.2%) 111 (73.5%) - - -
Radiotherapy 8 (2.8%) 7 (4.6%) - - -
Chemotherapy 22 (7.8%) - 2 (2.9%) 20 (66.7%) -
Severe adverse effects 48 (17.0%) 31 (20.5%) 4 (5.8%) * 10 (33.3%) 3 (9.4%) **
Dysphagia evolution
†
Regression at 2 months (n = 229) 139 (60.7%) 87 (64.0%) 25 (52.12%) 16 (55.2%) 11 (68.7%)
Recurrence (n = 103) 60 (58.2%) 35 (67.3%) 15 (68.2%) 7 (36.8%) 3 (30%)
n: number of patients, BSC: best supportive care, *: p < 0.05 curative treatment vs BSC,
**: p < 0.05 palliative treatment vs BSC, PDT: Phototherapy dynamic,
†: Many patients were not evaluable because they had died within 2 months
Figure 2 Overall survival. The median overall survival was 9.7 ± 1.0 months.
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events, the criteria used to select patient’s treatment
were appropriated and could be used in clinical practice.
Although treatment of elderly patients with EC may be
associated with an appreciable morbidity, at 75 years of
age considerable life expectancy remains (above 10
years) [17]. Then, elderly patients with EC may undergo
cancer treatment, and exclusion should be decided, as
for younger subjects, on an individual basis. Neverthe-
less in our series, after 80 years of age few patients
underwent an aggressive cancer treatment such as sur-
gery, chemotherapy or chemoradiotherapy.
Endoscopic resection and PDT are the treatments of
choice in most patients with mucosal EC [18,19] but
may also be used for T1N0M0 oesophageal carcinoma
with submucosal invasion as an alternative to surgery
in elderly patients with comorbidities [18]. The com-
plete response rate from was 40% to 80% [15,18,19]. In
our series, mucosectomy and PDT were an effective
treatment of early EC in elderly patients with 70% (n =
14/20) of complete response but 50% (n = 7/14) of
local recurrence. Surgical approach in patients older
than 70 years with oesophageal cancer remains debated
because of potentially higher post-operative complica-
tions [5,20,21]. As in our study, median survival after
esophagectomy remains poor in elderly patients, ran-
ging from 6 to 27 months with post-operative mortal-
ity ranging from 4.7% to 7.2% [22]. Average survival
almost approached the expected lifespan of a younger
cohort.
Definitive CRT is considered a feasible nonsurgical
treatment in patients with a locally advanced oesopha-
geal cancer and approximately a 50% to 65% CCR rate,
17 to 26 months of median overall survival and 30% to
40% 2-year survival rate [8,9,16]. Recently, two large
randomized trials investigated the efficacy of CRT, in
Table 4 Patient outcome and survival
All patients (n = 282) Patients without visceral metastasis
(n = 220)
Patients with visceral metastasis
(n = 62)
Curative treatment (n = 151) BSC
(n = 69)
Palliative treatment (n = 30) BSC
(n = 32)
Overall survival (month, SD) 9.7 ± 1.0 17.8 ± 1.5 5.5 ± 2.0 * 6.7 ± 2.1 1.8 ± 0.4 **
Specific survival (month, SD) 11.5 ± 0.7 23.2 ± 5.3 6.1 ± 2.5 * 6.7 ± 2.1 1.8 ± 0.4 **
Deaths 206 (73.0%) 113 (74.8%) 42 (60.9%) 24 (80.0%) 27 (84.4%)
Causes of death
cancer 181 (87.9%) 91 (80.5%) 40 (95.2%) 24 (100%) 26 (96.3%)
treatment 5 (2.4%) 3 (2.6%) 1 (2.4%) 0 1 (3.7%)
other 20 (9.7%) 19 (16.8%) 1 (2.4%) 0 0
n: number of patients, SD: standard deviation, BSC: best supportive care, *: p < 0.05 curative treatment vs BSC, **: p < 0.05 palliative treatment vs BSC
Figure 3 Overall survival according to treatment in non-metastatic patients. The median overall survival was 17.8 ± 1.5 months for patients
with curative treatment and 5.5 ± 2.0 months for patients with best supportive care (BSC).
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excluded and in Bedenne et al’s study there was no stra-
tification according to age of patients [8,9]. Interestingly,
our results in elderly patients were relatively close to
those reported in these studies. Anderson et al. and our
group reported significant results of CRT in elderly
patients in accordance with those in younger patients,
which suggested that this treatment can be proposed
with curative intent [10,11].
Chemotherapy in metastatic EC has poor efficacy and
has not been validated through large randomized trials;
moreover, there is no data reported in the literature on
chemotherapy tolerance and efficacy in elderly patients
with EC. In metastatic patients with median age 55-65
years, chemotherapy based on 5FU and cisplatin showed
a 20 to 40% response rate with a median overall survival
approximately 8-13 months. Adverse events grade ≥ 3
have been reported in 25-60% of cases [23]. In our
series, twenty patients had a palliative chemotherapy for
metastatic EC, seven experienced adverse effects ≥ grade
3 (35%) and seven (35%) had disease control at 3
months. Moreover, 5FU and cisplatin tolerance were
reported as the same in the elderly and younger patients
for advanced esophago-gastric cancer [24]. These results
are in agreement with those in younger patients and
underline the possible usefulness of chemotherapy in
selected elderly patients.
In France, approximately 20% of patients with EC
receive BSC alone and in the USA, 16% of patients over
65 years receive BSC alone [4]. These results of cancer
registry were probably underestimated. In our study,
35.8% (n = 101/282) of patients had BSC without any
specific cancer treatment.
To our knowledge, no previous study has investigated
therapeutic decisions in elderly patients with EC. In our
study, the main factors which influenced treatment
strategy were age, WHO performance status, nutritional
status and comorbidity. Using these criteria, few patients
experienced severe treatment-related complications. An
oncogeriatric assessment before treatment could be an
important tool for oncologists when making treatment
decisions, and it should be evaluated in EC. A clinical
score might be of appreciable help in clinical decisions.
According to our results, several criteria including age >
75 years, loss of weight > 10%, WHO performance sta-
t u s>1a n dC h a r l s o ns c o r e>1a r ec o n t r a d i c t i o n sf o r
aggressive treatment. These criteria need to be validated
by prospective analysis.
As reported in the literature, median overall survival is
poor (10 months) in elderly patients with an EC and
worse than in younger patients [4]. The main reported
predictive factors of overall survival were WHO perfor-
mance status, nutritional status and TNM stage [25,26].
No major difference was found in our multivariate ana-
lysis among elderly patients. Our group has previously
shown that baseline nutritional status is predictive of
response to treatment and survival in patients treated by
definitive CRT for a locally advanced oesophageal cancer
[26].
The major limitation of our study was that the retro-
spective analysis may have been based on incomplete
medical records. Nevertheless, the majority of non-avail-
able data were due to the patient’s death. Others limita-
tions are experience in a single institution, the small
sample size and the lack of pre-defined factors deter-
mining treatment decisions, which were based only on
evaluations by the referral doctor and members of
multi-disciplinary team. It should nonetheless be
recalled that the aim of the study was to retrospectively
identify the parameters to be associated with the key
therapeutic decision.
Table 5 Predictive factors of overall survival in univariate
and multivariate analysis
Univariate analysis
Median overall survival
Multivariate
analysis HR [95% CI]
Age ≥ 75 years ns
Sex ns
WHO
performance
status < 2
no 4.2 ± 0.2 * 1 [reference]
yes 17.8 ± 1.5 2.3 [1.6-3.4] *
Initial weight loss
< 10%
yes 6.3 ± 0.4 * 1 [reference]
no 17.5 ± 0.9 1.6 [1.1-2.3] *
Charlson score ≤
1
ns
Histology ns
Tumor stage
IV 4.2 ± 0.2 1 [reference]
III 10.7 ± 2.3 1.7 [1.1-2.6] *
II 15.2 ± 2.8 1.6 [1.1-2.5] *
I 67.7 ± 7.0 * 4.5 [1.9-11.1] *
Treatment
BSC 3.4 ± 0.3 * 1 [reference]
carcinologic
treatment
14.3 ± 3.3 4.4 [2.4-8.1] *
HR: Hazard ratio, CI: confidence interval, BSC: best supportive care, *: p < 0.05,
ns: not significant
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In conclusion, for the management of elderly patients
with an EC, in addition to age it is important to evalu-
ate nutritional status, performance status and comorbid-
ity before deciding therapeutic strategy. Our study
suggests that “selected elderly patients” with these
criteria should benefit from curative treatment because
there exists is no major related toxicity treatment and
similar treatment efficacy. Since our study is a retro-
spective analysis, these data warrant confirmation in
further series.
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